Rituximab in immunologic glomerular diseases

    Authors

    A. A. Ejaz; A. Asmar; M. M. Alsabbagh;N. Ahsan

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    mAbs

    Keywords

    rituximab; glomerular diseases; transplant; rejection; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IDIOPATHIC MEMBRANOUS NEPHROPATHY; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTIBODY-ASSOCIATED VASCULITIS; DEPENDENT NEPHROTIC SYNDROME; PROLIFERATIVE LUPUS NEPHRITIS; CHRONIC; LYMPHOCYTIC-LEUKEMIA; ANCA-ASSOCIATED VASCULITIS; B-CELL DEPLETION; RENAL-TRANSPLANTATION; Medicine, Research & Experimental

    Abstract

    Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology.

    Journal Title

    Mabs

    Volume

    4

    Issue/Number

    2

    Publication Date

    1-1-2013

    Document Type

    Review

    Language

    English

    First Page

    198

    Last Page

    207

    WOS Identifier

    WOS:000303594200003

    ISSN

    1942-0862

    Share

    COinS